Browse All

Current Filters

CLEAR FILTER x

TITLE

Reasons for Discontinuing Triptans Among Current Users of Rimegepant for the Acute Treatment of Migraine in the CONFIDENCE Study

Author:Hygge Blakeman, Karin   Urani, Alexandre   Lambru, Giorgio   Lipton, Richard   Goadsby, Peter   Pozo-Rosich, Patricia   Schwedt, Todd   Fanning, Kristina   Dai, Feng   Abraham, Lucy   

Session Name:P8: Headache: Acute, Rescue, and Short-term Prevention Migraine Pharmacologic Treatment  

Topic:Headache  

Program Number:P8.018  

Author Institution:Pfizer AB., Stockholm, Sweden  Aptar Digital Health, Paris, France  Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom  Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY  King’s College London, London, United Kingdom  Universitat Autònoma de Barcelona, Barcelona, Spain  Mayo Clinic, Phoenix, AZ  MIST Reserach, Wilmington, NC  Pfizer Inc., New York, NY  Pfizer R&D UK Ltd., Tadworth, United Kingdom